APHON CHEMOTHERAPY OVERVIEW
EXAM | QUESTIONS & ANSWERS
(VERIFIED) | LATEST UPDATE | GRADED
A+
Pre-clinical Studies
Correct Answer: purpose is to determine safe starting dose for humans
Folic Acid
Correct Answer: Positive effect on kids w/ lymphoblastic leukemia
Clinical trials
Correct Answer: comparing 2+ therapeutic tx in ctl setting to evaluate effect of
intervention of specific disease/s
Clinical Trial phase 1
Correct Answer: how much can you handle before breakdown?
determine max tolerated dose of drug or drug combo.
1
, ID dose-limiting toxicities: highest dose for which incidence of dose limiting toxicities is
<33%
Clinical Trial Phase 1 Patient
Correct Answer: advanced disease, good organ function, resistant to standard
therapies
Clinical Trial phase 2
Correct Answer: determines efficacy of new agent in tx of specific cancer types and
validate toxicity & dosage data. info r/t drug administration, acute toxicity, & supporting
care
Clinical Trial phase 2 Patient
Correct Answer: pt who show little to no response to prior tx usually selected w/
normal organ function, measurable tumor size, reasonable life expectancy & functional
status.
Includes pt who have not been treated w/ investigational drug
Clinical Trial Phase 3
Correct Answer: determine value of agent r/t existing tx. Measure response, toxicity,
survival & QOL
Clinical trial Phase 3 Patient
2
EXAM | QUESTIONS & ANSWERS
(VERIFIED) | LATEST UPDATE | GRADED
A+
Pre-clinical Studies
Correct Answer: purpose is to determine safe starting dose for humans
Folic Acid
Correct Answer: Positive effect on kids w/ lymphoblastic leukemia
Clinical trials
Correct Answer: comparing 2+ therapeutic tx in ctl setting to evaluate effect of
intervention of specific disease/s
Clinical Trial phase 1
Correct Answer: how much can you handle before breakdown?
determine max tolerated dose of drug or drug combo.
1
, ID dose-limiting toxicities: highest dose for which incidence of dose limiting toxicities is
<33%
Clinical Trial Phase 1 Patient
Correct Answer: advanced disease, good organ function, resistant to standard
therapies
Clinical Trial phase 2
Correct Answer: determines efficacy of new agent in tx of specific cancer types and
validate toxicity & dosage data. info r/t drug administration, acute toxicity, & supporting
care
Clinical Trial phase 2 Patient
Correct Answer: pt who show little to no response to prior tx usually selected w/
normal organ function, measurable tumor size, reasonable life expectancy & functional
status.
Includes pt who have not been treated w/ investigational drug
Clinical Trial Phase 3
Correct Answer: determine value of agent r/t existing tx. Measure response, toxicity,
survival & QOL
Clinical trial Phase 3 Patient
2
